Cañigral, G. (G.)

Filtering

20071

Settings

Author search.filters.isAuthorOfPublication.7e13f9af-28a0-4a16-a661-acdcb44a925f

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience
    (John Wiley and Sons, 2007) Gandarillas, M. (M.); Garcia, J. (Juan Carlos); Bergua, J. (Juan); Fernandez, P. (Pascual); Rodriguez, J. (José); Caballero, M.D. (M.D.); Albo, C. (Carmen); Morales, A. (Alfonso); Ribera, J.M. (José María); Carrera, D. (D,); Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO); Bendandi, M. (Maurizio); Arranz, R. (Reyes); Leon, A. (Angel); Sureda-Balari, A. M. (Anna Maria); Ojanguren, J. (Jesús); Moraleda, J. M. (José M.); Conde, E. (Eulogio); Gutierrez, A. (Antonio); Cañigral, G. (G.)
    Abstract OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) within the GELTAMO co-operative group between 1992 and 2004. METHODS: The median age at transplantation was 46 yr. Fifteen patients underwent the procedure as front-line therapy and four patients as salvage therapy. Most patients received peripheral stem cells (90%) coupled with BEAM or BEAC as conditioning regimen (79%). RESULTS: A 79% of patients achieved complete response, 5% partial response and 16% failed the procedure. After a median follow-up of 25 months, eight patients died (seven of progressive disease and secondary neoplasia), while actuarial overall survival and progression-free survival at 3 yr was 60% and 55%. Prognostic factors associated with a poor outcome included bone marrow involvement, transplantation in refractory disease state, attributing more than one factor of the age-adjusted-International Prognostic Index, Pretransplant peripheral T-cell lymphoma (PTCL) Score or Prognostic Index for PTCL. CONCLUSIONS: More than half of the patients with AIL that display unfavourable prognostic factors at diagnosis or relapse would be expected to be alive and disease-free after 3 yr when treated with HDC/ASCT. Patients who are transplanted in a refractory disease state do not benefit from this procedure.